STAT

Stem cell bank opens with backing from leading scientists. Is it worth the money?

Is it premature to start storing stem cells in the event they might be useful for treating diseases in the future?

The company’s roster of scientific advisers amounts to a who’s who of prominent stem cell experts, leading figures from Harvard and Stanford who are at the forefront of a field trying to turn basic discoveries into medical treatments of the future.

But instead of trying to develop new therapies itself, the company, LifeVault Bio, intends to store customers’ cells like treasured items in a well-sealed time capsule. The hope is that by preserving pristine cells before aging takes a toll on them, the cells could be used to treat customers should they one day develop heart disease or Parkinson’s or Alzheimer’s.

“We believe, and medicine is starting to believe, that this is really going to be a part of your health hygiene,” said LifeVault CEO Trevor Perry, predicting that stem cell banking will become as, as a form of “biological insurance”: “You insure a lot of things in your life, but have you taken out a policy on yourself?” Perry said.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.

Related Books & Audiobooks